Recursion Pharmaceuticals-a (RXRX)

$6.64

-0.3

(-4.32%)▲

Live

Performance

  • $6.61
    $6.85
    $6.64
    downward going graph

    0.53%

    Downside

    Day's Volatility :3.58%

    Upside

    3.07%

    downward going graph
  • $4.97
    $15.74
    $6.64
    downward going graph

    25.15%

    Downside

    52 Weeks Volatility :68.42%

    Upside

    57.81%

    downward going graph

Returns

PeriodRecursion Pharmaceuticals-aSector (Health Care)Index (Russel 2000)
3 Months
-14.74%
3.6%
0.0%
6 Months
-8.68%
10.2%
0.0%
1 Year
21.75%
19.6%
0.0%
3 Years
-62.2%
16.8%
-23.0%

Highlights

Market Capitalization
1.9B
Book Value
$2.08
Earnings Per Share (EPS)
-1.66
Wall Street Target Price
10.14
Profit Margin
0.0%
Operating Margin TTM
-697.39%
Return On Assets TTM
-34.35%
Return On Equity TTM
-71.18%
Revenue TTM
49.6M
Revenue Per Share TTM
0.22
Quarterly Revenue Growth YOY
30.9%
Gross Profit TTM
-164.1M
EBITDA
-364.9M
Diluted Eps TTM
-1.66
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.62
EPS Estimate Next Year
-1.78
EPS Estimate Current Quarter
-0.4
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Buy
    53%Buy
    46%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Recursion Pharmaceuticals-a(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 52.71%

Current $6.64
Target $10.14

Company Financials

FY19Y/Y Change
Revenue
1.7M
-
Net Income
-62.5M
-
Net Profit Margin
-3.7K%
-
FY20Y/Y Change
Revenue
3.4M
↑ 99.47%
Net Income
-87.9M
↑ 40.55%
Net Profit Margin
-2.6K%
↑ 1079.38%
FY21Y/Y Change
Revenue
10.0M
↑ 193.0%
Net Income
-178.1M
↑ 102.63%
Net Profit Margin
-1.8K%
↑ 794.18%
FY22Y/Y Change
Revenue
39.7M
↑ 296.81%
Net Income
-239.4M
↑ 34.45%
Net Profit Margin
-603.36%
↑ 1177.38%
FY23Y/Y Change
Revenue
44.6M
↑ 12.33%
Net Income
-328.1M
↑ 37.02%
Net Profit Margin
-735.99%
↓ 132.63%
Q1 FY23Q/Q Change
Revenue
12.1M
↓ 11.28%
Net Income
-60.8M
↑ 5.76%
Net Profit Margin
-500.98%
↓ 80.69%
Q2 FY23Q/Q Change
Revenue
11.0M
↓ 9.21%
Net Income
-76.7M
↑ 26.22%
Net Profit Margin
-696.5%
↓ 195.52%
Q3 FY23Q/Q Change
Revenue
10.1M
↓ 8.3%
Net Income
-93.0M
↑ 21.23%
Net Profit Margin
-920.78%
↓ 224.28%
Q4 FY23Q/Q Change
Revenue
10.9M
↑ 7.81%
Net Income
-93.0M
↓ 0.02%
Net Profit Margin
-853.88%
↑ 66.9%
Q1 FY24Q/Q Change
Revenue
13.8M
↑ 26.66%
Net Income
-91.4M
↓ 1.75%
Net Profit Margin
-662.41%
↑ 191.47%
Q2 FY24Q/Q Change
Revenue
14.4M
↑ 4.52%
Net Income
-97.5M
↑ 6.75%
Net Profit Margin
-676.56%
↓ 14.15%
FY19Y/Y Change
Total Assets
101.4M
-
Total Liabilities
225.7M
-
FY20Y/Y Change
Total Assets
298.6M
↑ 194.37%
Total Liabilities
504.9M
↑ 123.7%
FY21Y/Y Change
Total Assets
610.3M
↑ 104.41%
Total Liabilities
67.4M
↓ 86.65%
FY22Y/Y Change
Total Assets
701.3M
↑ 14.9%
Total Liabilities
215.5M
↑ 219.67%
FY23Y/Y Change
Total Assets
653.7M
↓ 6.79%
Total Liabilities
190.3M
↓ 11.7%
Q1 FY23Q/Q Change
Total Assets
627.4M
↓ 10.54%
Total Liabilities
197.2M
↓ 8.49%
Q2 FY23Q/Q Change
Total Assets
666.7M
↑ 6.27%
Total Liabilities
197.7M
↑ 0.28%
Q3 FY23Q/Q Change
Total Assets
630.8M
↓ 5.38%
Total Liabilities
192.9M
↓ 2.47%
Q4 FY23Q/Q Change
Total Assets
653.7M
↑ 3.63%
Total Liabilities
190.3M
↓ 1.35%
Q1 FY24Q/Q Change
Total Assets
557.8M
↓ 14.66%
Total Liabilities
156.7M
↓ 17.64%
Q2 FY24Q/Q Change
Total Assets
775.9M
↑ 39.08%
Total Liabilities
191.4M
↑ 22.16%
FY19Y/Y Change
Operating Cash Flow
-57.0M
-
Investing Cash Flow
-3.9M
-
Financing Cash Flow
120.4M
-
FY20Y/Y Change
Operating Cash Flow
-45.4M
↓ 20.41%
Investing Cash Flow
-8.7M
↑ 123.53%
Financing Cash Flow
246.1M
↑ 104.41%
FY21Y/Y Change
Operating Cash Flow
-158.6M
↑ 249.38%
Investing Cash Flow
-271.7M
↑ 3009.2%
Financing Cash Flow
458.5M
↑ 86.3%
FY22Y/Y Change
Operating Cash Flow
-83.5M
↓ 47.34%
Investing Cash Flow
193.2M
↓ 171.11%
Financing Cash Flow
154.3M
↓ 66.34%
Q1 FY23Q/Q Change
Operating Cash Flow
-73.3M
↑ 63.84%
Investing Cash Flow
-5.3M
↓ 33.07%
Financing Cash Flow
1.9M
↓ 98.69%
Q2 FY23Q/Q Change
Operating Cash Flow
-67.5M
↓ 7.98%
Investing Cash Flow
-2.1M
↓ 61.55%
Financing Cash Flow
3.8M
↑ 97.03%

Technicals Summary

Sell

Neutral

Buy

Recursion Pharmaceuticals-a is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Recursion Pharmaceuticals-a
Recursion Pharmaceuticals-a
4.05%
-8.68%
21.75%
-62.2%
-75.63%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Recursion Pharmaceuticals-a
Recursion Pharmaceuticals-a
NA
NA
NA
-1.62
-0.71
-0.34
NA
2.08
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Recursion Pharmaceuticals-a
Recursion Pharmaceuticals-a
Buy
$1.9B
-75.63%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Recursion Pharmaceuticals-a

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 10.10M → 14.41M (in $), with an average increase of 10.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -91.37M → -97.54M (in $), with an average decrease of 6.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 66.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 107.0%

Institutional Holdings

  • ARK Investment Management LLC

    9.97%

  • Baillie Gifford & Co Limited.

    9.42%

  • Vanguard Group Inc

    7.64%

  • BlackRock Inc

    6.13%

  • RA Capital Management, LLC

    5.45%

  • Mubadala Investment Company PJSC

    4.60%

Corporate Announcements

  • Recursion Pharmaceuticals-a Earnings

    Recursion Pharmaceuticals-a’s price-to-earnings ratio stands at None

    Read More

Company Information

recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.

Organization
Recursion Pharmaceuticals-a
Employees
500
CEO
Dr. Christopher C. Gibson Ph.D.
Industry
Services

Discover More

FAQs